What are GLP-1 Injections and How They Help 

The class of medications known as GLP-1 (glucagon-like peptide-1) receptor-agonists were originally developed for type 2 diabetes treatment. They work by mimicking the GLP-1 hormone, which is released in the gut after food, and which reduces appetite, slows gastric emptying and helps regulate blood sugar. Over recent years, these therapies have been adapted and approved for weight management in people without diabetes as well. 

At Hisential we offer supervised use of these injectable therapies as part of a comprehensive weight-management plan. However, they are not a magic bullet: success still depends on lifestyle change, nutrition, physical activity and regular follow-up. 

Second-Generation vs Third-Generation Injectable Therapies 

In the evolution of GLP-1 therapies for weight loss, we can loosely categorise “second-generation” versus emerging “third-generation” treatments (or dual/tri-agonist therapies) to help explain how the field is advancing. 

Second-Generation Injectables 

These newer GLP-1 receptor agonists (long-acting, once-weekly or similar) showed substantial weight-loss benefits compared to older first-generation diabetes drugs. For example, meta-analyses found that GLP-1 receptor agonists could reduce body weight by around 7.0 kg at 52 weeks in trials of mono-agonists. Another systematic review reported mean weight-loss reductions of about −8.47 kg with some of the more potent second-generation agents in people with type 2 diabetes. These therapies improved metabolic parameters, satiety, and reduced appetite in many individuals. 

Third-Generation / Dual- or Tri-Agonist Therapies 

The next wave of therapies build on the GLP-1 receptor mechanism by also targeting additional hormones (for example, GIP, glucagon or other pathways). Evidence suggests significantly greater weight-loss in many cases. A recent model-based meta-analysis found that, for example, tri-agonists had mean weight-reduction effects of up to around −22.6 kg at 52 weeks in obesity trials. In addition, a review noted that certain combined-agonist therapies achieved weight-loss beyond what the earlier GLP-1 mono-agonists could.  

What this means clinically 

In practical terms: second-generation therapies are highly useful and have established safety and efficacy. They may help many individuals achieve significant weight-loss (for example, in the range of 10-15% of body weight when combined with lifestyle change). Third-generation or dual/tri-agonist therapies offer the potential for greater weight-loss, potentially reaching 20% or more of body-weight reduction in selected individuals. At Hisential we assess each patient for suitability based on their medical history, weight loss goals, and willingness to commit to lifestyle change. 

We emphasise: whichever injectable is used, it is most effective when combined with nutrition, exercise, behavioural support and ongoing follow-up. 

Role of Nutrition, Lifestyle and Behaviour Change 

Injection therapy alone cannot sustain long-term weight management without lifestyle support. At Hisential Singapore, we integrate the following: 

• Personalised nutrition plan: based on your baseline weight, metabolic profile, food preferences and any medical conditions (e.g., diabetes, thyroid issues). We emphasise whole foods, adequate protein, fibre-rich vegetables, healthy fats and controlled carbohydrates. 

• Physical activity prescription: a mixture of aerobic, resistance and mobility training, tailored to your ability and starting level. Building lean muscle helps boost metabolism and improve body composition beyond just the scale. 

• Behavioural support and habit formation: learning mindful eating, managing emotional triggers for overeating, improving sleep hygiene, reducing stress and building sustainable habits rather than quick fixes. 

• Medical monitoring: regular follow-up visits to assess progress (weight, waist circumference, metabolic markers), adjust therapeutic dose if using injectables, and ensure safety. 

When injection therapy is combined with these lifestyle fundamentals, outcomes are markedly better with more weight loss, better health markers and greater likelihood of maintaining results long term. 

Why Early & Sustained Intervention Matters 

Obesity isn’t just about the number on the scale — it heightens your risk of type 2 diabetes, heart disease, certain cancers and joint problems. By intervening early with a comprehensive programme (rather than just diet “yo-yo”), you increase your chances of preserving lean muscle, improving metabolic health, lowering blood pressure and improving quality of life. 

Moreover, newer therapies mean you don’t have to wait years for results; the combination of injectables plus structured lifestyle support means you can see meaningful improvement within 3-6 months while still building sustainable habits for maintenance. 

Who is a Candidate at Hisential Singapore? 

We consider injectable therapies for weight management in patients who: 

• Have a BMI in the overweight or obese range (e.g., ≥27.5 kg/m² for Asians) and one or more weight-related health risks (hypertension, sleep apnoea, diabetes, dyslipidaemia); or 

• Have tried lifestyle change alone for a defined period (e.g., 6-12 months) without sufficient weight loss; and 

• Are motivated to engage with the lifestyle programme (nutrition, activity, follow-up) and understand the commitment involved. 

We do not recommend injectables alone without lifestyle change; nor are they appropriate for everyone (contraindications include certain thyroid, pancreatic or gastrointestinal conditions, pregnancy, or uncontrolled psychiatric illness). Our medical team assesses suitability on a case-by-case basis. 

Treatment Regimen: How the GLP-1 Program Works at Hisential Singapore 

Frequently Asked Questions About GLP-1 & Weight Loss Management

References

• Model-based meta-analysis of GLP-1R agonists and GLP-1/GIP/GCGR tri-agonists for obesity treatment. PubMed ID: 39980735 
• Efficacy and safety of GLP-1 receptor agonists in adults with type 2 diabetes mellitus: A systematic review and meta-analysis. PubMed ID: 38286487 
• Safety and tolerability of GLP-1 receptor agonists in patients with type 2 diabetes: Systematic review and meta-analysis. PubMed ID: 25089625 
• Obesity and Overweight – Fact Sheet. World Health Organization (2025) 
• What’s Your BMI? – HealthHub Singapore. Ministry of Health, Singapore